Advertisement
Apria conducted a competitive bid in which Masimo was selected due to thesuperior clinical performance of its proprietary Masimo SET pulse oximetrytechnology, which significantly enhances the ability of Apria's customers todetect hypoxic events in the home care setting. This will provide patientsand caregivers with reliable warnings of these instances where blood oxygenlevels begin to drop, which in turn will lead to expedient intervention andthe delivery of the appropriate level of care.
Advertisement
Masimo SET has been clinically proven in more than 100 independentclinical and laboratory studies to provide the most trustworthy continuousnoninvasive arterial blood oxygen saturation and pulse rate measurements evenunder the most difficult clinical conditions, including patient motion and lowperipheral perfusion. These studies prove Masimo SET delivers improvements inoutcomes, safety and efficiency by providing accurate measurement of arterialoxygen satuaration and pulse rate and significantly reducing false alarmswhile improving detection of true events.
Joe E. Kiani, Chairman & CEO of Masimo, stated, "We are happy that Apriahas chosen Masimo SET technology to help keep their patients safe in a homehealth care environment and are excited to be partnering with the leading namein home health care. This partnership with Apria marks Masimo's entry intothe home care market in the USA. Our mission has been to improve patientsafety and reduce cost of care by taking noninvasive monitoring to new sitesand applications. We are proud to form this partnership with Apria to bringreliable Masimo SET pulse oximetry into the home care setting."
About Masimo
Masimo develops innovative monitoring technologies that significantlyimprove patient care-helping solve "unsolvable" problems. In 1995, the companydebuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET,and with it substantially reduced false alarms and increased pulse oximetry'sability to detect life-threatening events. More than 100 independent clinicaland laboratory studies have confirmed that Masimo SET technology allowsclinicians to accurately monitor blood oxygen saturation in critical caresituations. Our Masimo SET platform has significantly addressed many of theprevious technology limitations, has substantially contributed to improvedpatient outcomes and has been referred to by several industry sources as thegold standard in pulse oximetry. In 2005, Masimo introduced Masimo Rainbow SETPulse CO-Oximetry, which, for the first time, noninvasively monitors the levelof carbon monoxide and methemoglobin in the blood, allowing early detectionand treatment of potentially life-threatening conditions. Founded in 1989,Masimo has the mission of "Improving Patient Outcomes and Reducing Cost ofCare by Taking Noninvasive Monitoring to New Sites and Applications."Additional information about Masimo and its products may be found athttp://www.masimo.com.
Masimo, SET, Signal Extraction Technology, Radical, Radical-7, Rad57,APOD, and Improving Outcomes and Reducing Cost of Care by Taking NoninvasiveMonitoring to New Sites and Applications are registered trademarks of MasimoCorporation. ARM, Acoustic Respiratory Monitoring, BiFi, Rainbow, SpCO, SpMet,SpHb and Pulse CO-Oximeter are trademarks of Masimo Corporation.Contact: Tom McCall Masimo Corpora
